Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Scilex Holding Company - Warrant
No Price
28.04.2026 19:31
Current Prices from Scilex Holding Company - Warrant
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ
SCLXW
USD
28.04.2026 19:31
0,17 USD
0,01 USD
+6,78 %
IEX
SCLXW
USD
21.04.2026 15:37
0,15 USD
-
Share Float & Liquidity
Free Float82,54 %
Shares Float7,01 M
Shares Outstanding8,49 M
Company Profile for Scilex Holding Company - Warrant Share
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
